Why the hip ChondroFiller injection sits outside the NHS

ChondroFiller injection is not available on the NHS for hip cartilage repair anywhere in the UK. The short answer to that question is straightforward: NHS commissioning for cartilage-matrix treatments — such as autologous chondrocyte implantation (ACI) — covers the knee joint only. For the hip, the commissioned pathway moves from conservative management (physiotherapy, analgesia, steroid injections) directly to total hip replacement when conservative measures no longer suffice. Regenerative biologics for the hip joint sit outside that commissioned pathway entirely.

This is not a reflection of ChondroFiller's regulatory standing. The product is a CE-marked Class III medical device, manufactured by Meidrix Biomedicals in Germany and imported into the UK under prescription. The private-only position reflects NHS commissioning priorities, not any question about clinical legitimacy or legal approval.

For hip patients in Lincolnshire and across the wider UK, that gap in commissioning creates a practical problem: those with focal cartilage defects — not yet at the stage where total hip replacement is appropriate — have no funded route to a joint-preservation option that sits between symptom management and surgery. ChondroFiller injection occupies precisely that space: an ultrasound-guided, outpatient collagen scaffold treatment aimed at focal defects in the hip joint, funded either as self-pay or through private medical insurance.

What ChondroFiller injection costs across the UK

Pricing varies by provider, location, and — most importantly — how much product a patient's defect requires.

London providers

London Cartilage Clinic, which was the first UK centre to offer ChondroFiller as an injection, publishes all-inclusive tariffs: £3,000 for one box, £5,500 for two boxes, and £8,000 for three. Each price covers the consultation, ultrasound guidance, the product itself, the injection, intravenous antibiotic cover, and a six-week follow-up appointment — there are no separately billed procedure fees on top of that.

Liquid Cartilage, also on Harley Street, quotes from £2,800 for a large-joint injection including the hip. Both centres also offer an arthroscopic delivery route — quoted at around £9,500 — but that is a distinct surgical pathway performed in an operating theatre under anaesthesia, not the standard outpatient injection route. Patients comparing quotes should confirm which route each figure refers to.

Volume is the main cost driver

The number of boxes required depends on the size of the cartilage defect identified on MRI. A single-box quote and a three-box quote are not like-for-like comparisons; the appropriate volume can only be determined after imaging and clinical assessment.

Lincolnshire access

MSK Doctors at The Keep Clinic, Grantham, is the identified local provider, with the procedure reported at approximately £2,500. Patients should confirm the current tariff directly with the clinic before making financial plans, as pricing is subject to change.

Costs that may sit outside headline quotes

A pre-procedure MRI is mandatory for all patients and is typically billed separately. An initial consultation fee — usually £150–£250 — may also fall outside the procedure price. For Lincolnshire patients whose treatment is performed in London, travel and accommodation add further expense.

The Lincolnshire access pathway in practice

For a Lincolnshire patient, the practical journey towards a ChondroFiller injection for the hip follows a hub-and-spoke structure: local assessment and diagnostics close to home, specialist treatment in London, then follow-up and rehabilitation back in Lincolnshire.

The process begins with an initial consultation at The Keep Clinic, Grantham (The Old Barracks, Sandon Road, NG31 9AS), where MSK Doctors offers hip assessment without a GP referral letter — patients can self-refer directly. At this stage, the clinician takes a full history, reviews symptoms, and discusses whether a regenerative scaffold approach may be appropriate.

A pre-procedure MRI is then arranged. This imaging is central to candidacy: it confirms the defect size, identifies the Tönnis OA grade, and establishes whether the patient has a focal, contained lesion suited to an injectable collagen scaffold or whether more diffuse arthritis puts them outside the treatable window. Patients with Tönnis grade 2–3 changes tend to have poor outcomes, and candidacy discussion following the MRI is where that distinction is made.

If the MRI findings support proceeding, the ChondroFiller injection itself is typically performed at a specialist centre — most commonly on Harley Street, London — as an ultrasound-guided outpatient procedure under local anaesthetic. The patient travels to London for the treatment day, usually returning home the same day.

Post-injection follow-up and rehabilitation can then continue locally through the MSK Doctors network, keeping the recovery phase manageable for patients outside the capital.

Insurance and PMI cover for ChondroFiller injection in the hip

Private medical insurance cover for ChondroFiller injection is possible, but it is neither routine nor guaranteed — and the position of individual insurers can shift without notice.

Bupa, Aviva, and WPA have each been reported to approve ChondroFiller injection on a case-by-case basis. When approvals are granted, the procedure is typically billed under CCSD code W3111 (cartilage regeneration with collagen scaffold) or W8500 (arthroscopy), or a combination of both. These codes are worth having to hand when calling an insurer, as billing terminology matters for pre-authorisation.

That said, at least one UK provider — London Cartilage Clinic — formally describes ChondroFiller as a self-funded private treatment that sits outside standard NHS and PMI coverage. This reflects the reality that insurer stances are not uniform and a precedent at one insurer does not apply to others.

The safest working assumption is self-pay unless written confirmation of coverage has been obtained for this specific procedure and CCSD code before any booking is made. A generic policy approval for 'joint injections' may not extend to an injectable collagen scaffold procedure.

Patients checking their cover should ask their insurer specifically whether their policy covers 'injectable collagen scaffold for hip cartilage repair', quote the relevant CCSD code, and request written pre-authorisation before arranging a consultation or procedure date.

Which hip patients are suitable — and who is not

Selecting the right patient matters as much as the treatment itself. ChondroFiller injection is designed for focal, contained articular cartilage defects — typically Grade III or IV lesions on the acetabular surface or femoral head where the surrounding cartilage and underlying bone remain reasonably intact. The CE clinical evaluation report supports defect coverage up to 3 cm², with extension to 6 cm² in certain cases; defects well beyond that range are unlikely to benefit adequately from a single injectable scaffold.

Age is a useful guide rather than a hard cutoff. Patients under roughly 50–55 with a clearly defined focal defect and low-to-moderate OA burden tend to be the strongest candidates: their joints still offer the structural environment that allows the collagen scaffold to recruit host cells effectively over the six-to-twelve-month regenerative window.

At the other end of the spectrum, the published evidence is equally instructive. In the prospective hip cohort by Hnátek et al. in the Journal of Hip Preservation Surgery (2021, n=26, 3–5 year follow-up), patients with pre-existing Tönnis grade 2–3 osteoarthritis fared poorly — confirming that ChondroFiller injection is a joint-preservation strategy for the right candidate, not a rescue treatment for diffuse, end-stage hip disease. Patients for whom total hip replacement is already clearly indicated are similarly unlikely to gain meaningful benefit from this approach. That hip-specific evidence base, while encouraging, currently rests on relatively small prospective cohorts and no large randomised controlled trial has yet been completed — a limitation worth calibrating openly with a clinician before committing to a treatment plan.

Starting the process as a Lincolnshire patient — what to expect

Before a first appointment, gathering a few items will make the consultation more useful. An existing hip MRI taken within the past twelve months is the most valuable thing to bring — if imaging has not yet been arranged, it can be organised locally as part of the initial assessment. A written list of symptoms and their duration, any previous treatments tried (physiotherapy, injections, pain medication), and GP correspondence if available all help the clinician build a clear baseline quickly. A GP referral letter is not required for self-referral.

The consultation itself focuses on confirming diagnosis, OA grade, and — most critically — whether the defect's size and location on MRI fall within the range where an injectable collagen scaffold approach is likely to be useful. Patients whose hip has moved beyond the preservation window are identified at this stage and directed to the appropriate pathway rather than an unsuitable treatment.

When a patient is found suitable, the treatment plan and pricing are confirmed at that same appointment, and the London injection day scheduled. Post-injection, a period of protected weight-bearing and progressive rehabilitation follows; local physiotherapy can be arranged through Lincolnshire Hip. For self-pay patients, the gap between first contact and treatment typically runs to weeks rather than months. Lincolnshire Hip accepts hip assessments without a GP referral, so that timeline can start at the patient's own initiative.

1. [1] Ex Vivo Osteochondral Biomimetic Platform for Cartilage Regeneration (ChondroFiller®). (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
2. [2] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002